Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ACT
|
|||
| Former ID |
DIB001664
|
|||
| Drug Name |
PRS-211375 iv
|
|||
| Synonyms |
Cannabinor; Bicyclic cannabinoids, Pharmos; HU-308; PRS-211058; PRS-211096; PRS-211335; PRS-211359; PRS-211375; CB2-selective cannabinoid platform, Pharmos; Oral Cannabinor (pain), Pharmos; PRS-211375 (oral, pain), Pharmos; PRS-211375 (iv, inflammation/autoimmune disease), Pharmos
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Discontinued in Phase 2 | [1], [2] | |
| Company |
Pharmos
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H42O3
|
|||
| Canonical SMILES |
CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)C2C=C(C3CC2C3(C)C)CO)OC
|
|||
| InChI |
1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
|
|||
| InChIKey |
CFMRIVODIXTERW-FDFHNCONSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 2 (CB2) | Target Info | Agonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 746). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021026) | |||
| REF 3 | Brain CB2 Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) 2010 August; 3(8): 2517-2553. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.